QT interval prolongation and torsade de pointes associated with indapamide - PubMed

• PMID: 16260053
• DOI: 10.1016/j.ijcard.2005.07.055

Case Reports

QT interval prolongation and torsade de pointes associated with indapamide

Konstantinos P Letsas et al. Int J Cardiol. 2006.

Abstract

Direct blockade of the delayed rectifier repolarising potassium current is the major underlying mechanism of drug-induced QT interval prolongation. Indapamide is a well known blocker of the slow component of the delayed rectifier current leading to prolongation of cardiac repolarization. The case of an acquired long QT and torsade de pointes ventricular tachycardia in a woman with systemic lupus erythematosus and hypertension receiving prednisolone and indapamide, respectively, is described in the present report.

Comment in

• QT interval prolongation and torsade de pointes associated with indapamide. Comments to Letsas et al.

  Perciaccante A, Fiorentini A. Perciaccante A, et al. Int J Cardiol. 2007 Nov 30;122(3):255; author reply 256-7. doi: 10.1016/j.ijcard.2006.11.245. Epub 2007 Mar 21. Int J Cardiol. 2007. PMID: 17368589 No abstract available.

Similar articles

• [Severe ventricular arrhythmia secondary to indapamide-induced hypopotassemia].

  Guzzini F, Baroffio R, Coppetti D, Gasparini P. Guzzini F, et al. Clin Ter. 1990 Nov 30;135(4):283-7. Clin Ter. 1990. PMID: 1705875 Italian.

• QT interval prolongation, torsade de pointes and renal disease.

  Patanè S, Marte F, Di Bella G, Currò A, Coglitore S. Patanè S, et al. Int J Cardiol. 2008 Nov 12;130(2):e71-3. doi: 10.1016/j.ijcard.2007.11.070. Epub 2008 Feb 5. Int J Cardiol. 2008. PMID: 18255176

• QT interval prolongation and torsade de pointes associated with indapamide. Comments to Letsas et al.

  Perciaccante A, Fiorentini A. Perciaccante A, et al. Int J Cardiol. 2007 Nov 30;122(3):255; author reply 256-7. doi: 10.1016/j.ijcard.2006.11.245. Epub 2007 Mar 21. Int J Cardiol. 2007. PMID: 17368589 No abstract available.

• Drug-induced QT prolongation and proarrhythmia: an inevitable link?

  Ahmad K, Dorian P. Ahmad K, et al. Europace. 2007 Sep;9 Suppl 4:iv16-22. doi: 10.1093/europace/eum167. Europace. 2007. PMID: 17766320 Review.

• Drug-induced long QT syndrome and torsade de pointes.

  Morissette P, Hreiche R, Turgeon J. Morissette P, et al. Can J Cardiol. 2005 Aug;21(10):857-64. Can J Cardiol. 2005. PMID: 16107909 Review.

Cited by

• Modulation of the QT interval duration in hypertension with antihypertensive treatment.

  Klimas J, Kruzliak P, Rabkin SW. Klimas J, et al. Hypertens Res. 2015 Jul;38(7):447-54. doi: 10.1038/hr.2015.30. Epub 2015 Mar 19. Hypertens Res. 2015. PMID: 25787045 Review.

• Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias.

  Cubeddu LX. Cubeddu LX. Curr Cardiol Rev. 2016;12(2):141-54. doi: 10.2174/1573403x12666160301120217. Curr Cardiol Rev. 2016. PMID: 26926294 Free PMC article. Review.

• Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

  Cubeddu LX. Cubeddu LX. Curr Cardiol Rev. 2009 Aug;5(3):166-76. doi: 10.2174/157340309788970397. Curr Cardiol Rev. 2009. PMID: 20676275 Free PMC article.

• Long QT Syndrome: An Emerging Role for Inflammation and Immunity.

  Lazzerini PE, Capecchi PL, Laghi-Pasini F. Lazzerini PE, et al. Front Cardiovasc Med. 2015 May 27;2:26. doi: 10.3389/fcvm.2015.00026. eCollection 2015. Front Cardiovasc Med. 2015. PMID: 26798623 Free PMC article. Review.

• Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.

  Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, Dimopoulos NP, Filippatos GS, Sideris A, Kardaras F. Letsas KP, et al. Clin Res Cardiol. 2009 Apr;98(4):208-12. doi: 10.1007/s00392-008-0741-y. Epub 2008 Nov 24. Clin Res Cardiol. 2009. PMID: 19031039

Publication types

MeSH terms

Substances